Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Willy Lescaut"'
Autor:
Dominique Berton, Anne Floquet, Willy Lescaut, Gabriel Baron, Marie-Christine Kaminsky, Philippe Toussaint, Rémy Largillier, Aude-Marie Savoye, Jérôme Alexandre, Catherine Delbaldo, Emmanuelle Malaurie, Hugues Barletta, Claire Bosacki, Claire Garnier-Tixidre, Philippe Follana, Hortense Laharie-Mineur, Charles Briac Levache, Bruno Valenza, Agnès Dechartres, Delphine Mollon-Grange, Frédéric Selle
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study as
Externí odkaz:
https://doaj.org/article/759e5d59f76b40d9ba13a0b2c9ebd372
Autor:
E. Malaurie, Claire Bosacki, Aude-Marie Savoye, Claire Garnier-Tixidre, Philippe Toussaint, Agnès Dechartres, Rémy Largillier, Gabriel Baron, Marie-Christine Kaminsky, Dominique Berton, Bruno Valenza, Willy Lescaut, Hortense Laharie-Mineur, Jérôme Alexandre, Anne Floquet, Frédéric Selle, Charles Briac Levache, Hugues Barletta, Philippe Follana, Delphine Mollon-Grange, Catherine Delbaldo
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Frontiers, 2021, 12, ⟨10.3389/fphar.2021.711813⟩
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Frontiers, 2021, 12, ⟨10.3389/fphar.2021.711813⟩
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study as
Autor:
Jérôme, Barrière, Clarisse, Audigier-Valette, Delphine, Borchiellini, Benjamin, Hoch, Olivier, Castelnau, Eric, Francois, Lauris, Gastaud, Richard, Skaf, Jean-François, Berdah, Wislez, Marie, Willy, Lescaut, Frédéric, Peyrade, Thomas, Cluzeau, Ophélie, Cassuto, Michel, Carles
Publikováno v:
Bulletin du Cancer
Autor:
Thomas Cluzeau, Olivier Castelnau, Jérôme Barrière, Richard Skaf, J. F. Berdah, Michel Carles, Delphine Borchiellini, Frederic Peyrade, Eric Francois, Clarisse Audigier-Valette, Willy Lescaut, Lauris Gastaud, Wislez Marie, Benjamin Hoch, Ophelie Cassuto
Publikováno v:
Bulletin du Cancer. 108:341-342
Autor:
Marie J Chammas, Emily Pesek, Robert J. Soiffer, Veronika Bachanova, Abraham Avigdor, Joseph H. Antin, Armando Santoro, Philippe Armand, Willy Lescaut, Anne Thiebaut-Bertrand, Stephen M. Ansell, Jerome Ritz, Pier Luigi Zinzani, Reid W. Merryman, Ahmad Halwani, Miguel-Angel Perales, Scott C. Bresler, Harim Kim, L. Castagna, Amitabh Srivastava, Vincent T. Ho, Haesook T. Kim, Roch Houot, Aspasia Stamatoullas-Bastard, Carol Reynolds, Pierre-Simon Rohrlich, Carmelo Carlo-Stella, Nathalie Dhedin, Hélène Labussière Wallet, Tony Marchand, Sylvie François
Publikováno v:
Blood
Blood, American Society of Hematology, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩
Blood, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩
Blood, American Society of Hematology, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩
Blood, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩
International audience; Anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be36b519c34b9ebc42d3160174216b3
https://europepmc.org/articles/PMC5345733/
https://europepmc.org/articles/PMC5345733/